

Manuela Merli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8700351/publications.pdf>

Version: 2024-02-01

341
papers

16,052
citations

12303

69
h-index

19136

118
g-index

352
all docs

352
docs citations

352
times ranked

10081
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of falls in patients with cirrhosis evaluated by timed up and go test: Does muscle or brain matter more?. Digestive and Liver Disease, 2022, 54, 371-377.	0.4	8
2	Sarcopenia in chronic advanced liver diseases: A sex-oriented analysis of the literature. Digestive and Liver Disease, 2022, 54, 997-1006.	0.4	5
3	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. American Journal of Transplantation, 2022, 22, 1191-1200.	2.6	29
4	Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy. Journal of Clinical Medicine, 2022, 11, 611.	1.0	10
5	Risk factors for hepatic encephalopathy and mortality in cirrhosis: The role of cognitive impairment, muscle alterations and shunts. Digestive and Liver Disease, 2022, 54, 1060-1065.	0.4	12
6	Hemodynamic Evaluation of the Right Heart-Pulmonary Circulation Unit in Patients Candidate to Transjugular Intrahepatic Portosystemic Shunt. Journal of Clinical Medicine, 2022, 11, 461.	1.0	2
7	Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis. Journal of Clinical and Experimental Hepatology, 2022, 12, 1293-1300.	0.4	3
8	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	1.8	76
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
10	Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. European Journal of Clinical Investigation, 2021, 51, e13356.	1.7	6
11	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	1.8	38
12	Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver. Journal of Clinical and Experimental Hepatology, 2021, 11, 97-143.	0.4	36
13	Comparison of Up-to-seven criteria with Milan Criteria for liver transplantation in patients with HCC. Trends in Transplantation, 2021, 14, .	0.2	3
14	Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report. Australasian Journal of Dermatology, 2021, 62, e442-e443.	0.4	2
15	Pregnancy after liver transplantation: a survey from Italian liver transplants centres. Digestive and Liver Disease, 2021, 53, S12-S13.	0.4	0
16	The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease. Modern Gastroenterology, 2021, , .	0.1	0
17	Liver transplant recipients with Covid-19: results from an Italian multicenter cohort. Digestive and Liver Disease, 2021, 53, S13.	0.4	0
18	Treatment of CRKP infections in cirrhotic patients. Digestive and Liver Disease, 2021, 53, S42.	0.4	0

#	ARTICLE	IF	CITATIONS
19	SarcoModel: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation. <i>Liver International</i> , 2021, 41, 1629-1640.	1.9	17
20	The European Society for Clinical Nutrition and Metabolism practical guideline: Clinical nutrition in liver disease. Part 2. <i>Modern Gastroenterology</i> , 2021, , .	0.1	3
21	Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , 2021, 3, 100264.	2.6	35
22	Acute rejection on immune-mediated chronic rejection after liver transplantation. <i>Gazzetta Medica Italiana Archivio Per Le Scienze Mediche</i> , 2021, 180, .	0.0	0
23	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	1.8	15
24	The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. <i>Nutrients</i> , 2021, 13, 2296.	1.7	11
25	Sarcopenia and frailty in decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S147-S162.	1.8	145
26	The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. <i>Liver International</i> , 2021, 41, 2965-2973.	1.9	33
27	Cumulative incidence of solid and hematological De novo malignancy after liver transplantation in a multicentre cohort. <i>Annals of Hepatology</i> , 2021, 24, 100309.	0.6	4
28	Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study. <i>Digestive and Liver Disease</i> , 2021, , .	0.4	0
29	Reply to: "The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites". <i>JHEP Reports</i> , 2021, 3, 100349.	2.6	1
30	Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease. <i>Life</i> , 2021, 11, 1200.	1.1	7
31	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 963-973.e14.	2.4	77
32	Pediatric sarcopenia: exploring a new concept in children with chronic liver disease. <i>Jornal De Pediatria</i> , 2020, 96, 406-408.	0.9	8
33	Pediatric sarcopenia: exploring a new concept in children with chronic liver disease. <i>Jornal De Pediatria (Versão Em Português)</i> , 2020, 96, 406-408.	0.2	0
34	The role of liver stiffness by ARFI elastography in the diagnosis of porto-sinusoidal vascular disease: comparison with patients with chronic portal vein thrombosis. <i>Journal of Hepatology</i> , 2020, 73, S556.	1.8	0
35	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
36	Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study. <i>Journal of Hepatology</i> , 2020, 73, S690.	1.8	0

#	ARTICLE	IF	CITATIONS
37	ESPEN practical guideline: Clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2020, 39, 3533-3562.	2.3	170
38	Sustained virological response with DAAs decreases glucose level but do not improve renal function, lipid metabolism and blood pressure in liver transplanted patients: a 3-year, long-term follow up. <i>Journal of Hepatology</i> , 2020, 73, S275-S276.	1.8	0
39	T06.01.7 TRANSVERSAL PSOAS MUSCLE THICKNESS AND SKELETAL MUSCLE INDEX, A COMPARISON OF TWO TOLL FOR THE DIAGNOSIS OF SARCOPENIA IN CIRRHOSIS. <i>Digestive and Liver Disease</i> , 2020, 52, S160.	0.4	0
40	T06.01.11 THE QUADRICEPS MUSCLE ULTRASOUND IN THE DIAGNOSIS OF SARCOPENIA IN PATIENTS WITH LIVER CIRRHOSIS. <i>Digestive and Liver Disease</i> , 2020, 52, S162-S163.	0.4	0
41	T06.01.18 EFFECTS OF BETA-HYDROXY-BETA-METHYLBUTYRATE SUPPLEMENTATION IN PATIENTS WITH LIVER CIRRHOSIS: A RANDOMIZED CONTROLLED PILOT STUDY. <i>Digestive and Liver Disease</i> , 2020, 52, S166.	0.4	0
42	Nutrition in cirrhosis: Dos and Donâ€™ts. <i>Journal of Hepatology</i> , 2020, 73, 1563-1565.	1.8	9
43	Comparison of skeletal muscle index (SMI) and transversal psoas muscle thickness (TPMT) for the diagnosis of sarcopenia in cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S688-S689.	1.8	0
44	The diagnosis of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S709.	1.8	0
45	Nutrition in Liver Cirrhosis and Transplantationâ€™Current State and Knowledge Gaps. <i>Nutrients</i> , 2020, 12, 680.	1.7	1
46	VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen. <i>Digestive and Liver Disease</i> , 2020, 52, e2-e3.	0.4	0
47	New and old therapy against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> (kpc) infections in the cirrhotic patient: a retrospective analysis. <i>Digestive and Liver Disease</i> , 2020, 52, e36.	0.4	0
48	Nutritional Therapy in the Management of Physical Frailty and Sarcopenia. , 2020, , 77-85.		0
49	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, 172-193.	1.8	608
50	Hepatic Encephalopathy and Sarcopenia: Two Faces of the Same Metabolic Alteration. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 125-130.	0.4	41
51	FRI-398-Impact of sarcopenia and myosteatosis on post-transplant complications and survival. <i>Journal of Hepatology</i> , 2019, 70, e570.	1.8	0
52	FRI-369-The role of adipose tissue in metabolic and cardiovascular complication after liver transplantation. <i>Journal of Hepatology</i> , 2019, 70, e557.	1.8	0
53	The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1508-1512.	0.4	34
54	The Effect of 12 Weeks of Î²-Hydroxy-Î²-Methyl-Butyrate Supplementation after Liver Transplantation: A Pilot Randomized Controlled Study. <i>Nutrients</i> , 2019, 11, 2259.	1.7	22

#	ARTICLE	IF	CITATIONS
55	SAT-039-The assessment of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e643-e644.	1.8	0
56	The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. <i>Liver International</i> , 2019, 39, 871-877.	1.9	55
57	ESPEN guideline on clinical nutrition in liver disease. <i>Clinical Nutrition</i> , 2019, 38, 485-521.	2.3	387
58	Donor Small-Droplet Macrovesicular Steatosis Affects Liver Transplant Outcome in HCV-Negative Recipients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-13.	0.8	9
59	Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. <i>Liver International</i> , 2019, 39, 1937-1942.	1.9	14
60	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	0.6	178
61	FRI-428-Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e582.	1.8	1
62	SAT-088-Sarcopenia and Myosteatorosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e666-e667.	1.8	0
63	Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>Hepatology</i> , 2019, 70, 1704-1713.	3.6	105
64	Acquired cow's milk sensitization after liver transplant in an adult: clinical implications and future strategies. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 11.	0.9	0
65	Reply. <i>Hepatology</i> , 2019, 70, 762-763.	3.6	1
66	MRI reveals different Crohn's disease phenotypes in children and adults. <i>European Radiology</i> , 2019, 29, 5082-5092.	2.3	17
67	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	0.6	296
68	P: 25 Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2019, 114, S13-S13.	0.2	1
69	P: 26 The Modification of Quantity and Quality of Muscle Mass Improves the Cognitive Impairment After TIPS. <i>American Journal of Gastroenterology</i> , 2019, 114, S14-S14.	0.2	0
70	Weight Gain and De Novo Metabolic Disorders after Liver Transplantation. <i>Nutrients</i> , 2019, 11, 3015.	1.7	11
71	Sarcopenic obesity in fatty liver. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2019, 22, 185-190.	1.3	36
72	Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00025.	1.3	87

#	ARTICLE	IF	CITATIONS
73	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.4	77
74	Extended Infusion of β -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1731-1739.	2.9	29
75	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	1.8	225
76	Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. <i>Hepatology</i> , 2019, 70, 640-649.	3.6	74
77	Presence of sarcopenia is associated with development of acute-on-chronic liver failure in the NEPTUN cohort. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.2	0
78	May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?. <i>Journal of Hepatology</i> , 2018, 68, 1324-1325.	1.8	1
79	Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. <i>Digestive and Liver Disease</i> , 2018, 50, 839-844.	0.4	52
80	A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. <i>Liver International</i> , 2018, 38, 851-857.	1.9	45
81	Determinants of clinical efficacy of empirical antibiotic treatment in patients with cirrhosis and bacterial infections: Results from the ICA global study. <i>Journal of Hepatology</i> , 2018, 68, S691-S692.	1.8	0
82	The multidisciplinary support in preventing alcohol relapse after liver transplantation: A single-center experience. <i>Clinical Transplantation</i> , 2018, 32, e13243.	0.8	22
83	Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation. <i>Journal of Hepatology</i> , 2018, 68, S389.	1.8	1
84	Nutritional Assessment and Management for Hospitalized Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2018, 17, 88-96.	0.4	3
85	Epidemiology, predictors and outcomes of multi drug resistant bacterial infections in patients with cirrhosis across the world. Final results of the "Global study". <i>Journal of Hepatology</i> , 2018, 68, S1.	1.8	16
86	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 546.e1-546.e8.	2.8	67
87	Fluctuations of Estimated Glomerular Filtration Rate Outside Kidney Disease Improving Global Outcomes Diagnostic Criteria for Acute Kidney Injury in End-Stage Liver Disease Outpatients and Outcome Postliver Transplantation. <i>Transplantation Direct</i> , 2018, 4, e222.	0.8	0
88	The assessment of Sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis. <i>Clinical Nutrition</i> , 2018, 37, S302-S303.	2.3	2
89	Ischemic Damage Represents the Main Risk Factor for Biliary Stricture After Liver Transplantation: A Follow-Up Study in a Danish Population. <i>In Vivo</i> , 2018, 32, 1623-1628.	0.6	4
90	Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1146-1155.	1.9	14

#	ARTICLE	IF	CITATIONS
91	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345
92	Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. <i>Scientific Reports</i> , 2018, 8, 8210.	1.6	63
93	Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections. <i>Journal of Hepatology</i> , 2018, 68, S253-S254.	1.8	4
94	Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?. <i>Journal of Hepatology</i> , 2018, 69, 567-569.	1.8	7
95	Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA Global Study. <i>Journal of Hepatology</i> , 2018, 68, S46-S47.	1.8	0
96	Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: Real life data from the ICONA/HepalCONA Foundation cohorts. <i>Journal of Hepatology</i> , 2018, 68, S299-S300.	1.8	1
97	Impact of an antimicrobial stewardship policy on the reduction of empirical antibiotic treatment failure and the spread of multidrug-resistant organisms in hospitalized cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, S725-S726.	1.8	0
98	The effect of new infection control measures for the prevention of hospital acquired infections in cirrhotic patients. <i>Journal of Hepatology</i> , 2018, 68, S747.	1.8	0
99	Tu1182 PREDICTIVE FACTORS FOR THE ERADICATION OF ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS UNDERGOING ENDOSCOPIC BAND LIGATION.. <i>Gastrointestinal Endoscopy</i> , 2018, 87, AB558.	0.5	0
100	Outbreak of acute hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics. <i>Journal of Hepatology</i> , 2018, 68, S33.	1.8	1
101	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. <i>Journal of Hepatology</i> , 2018, 68, S44-S45.	1.8	2
102	A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. <i>Journal of Hepatology</i> , 2018, 68, S606.	1.8	0
103	Is obesity an additional negative factor in sarcopenic cirrhotic patients?. <i>Journal of Hepatology</i> , 2018, 68, S739.	1.8	0
104	Regional variations in the development of acute-on-chronic liver failure (ACLF) in patients with cirrhosis and bacterial infections. <i>Journal of Hepatology</i> , 2018, 68, S236-S237.	1.8	1
105	Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1536-1537.	1.9	2
106	The amelioration of muscle wasting leads to the improvement of cognitive impairment after transjugular intrahepatic portosystemic shunt: A proof of concept that sarcopenia and hepatic encephalopathy are causally related. <i>Journal of Hepatology</i> , 2018, 68, S700-S701.	1.8	1
107	Donor-to-recipient gender match in liver transplantation: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 2203-2210.	1.4	28
108	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84

#	ARTICLE	IF	CITATIONS
109	Reply to: "Myokines: a promising therapeutic target for hepatic encephalopathy". <i>Journal of Hepatology</i> , 2017, 66, 1100-1101.	1.8	0
110	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	1.0	11
111	MELDNa score is associated with psychopathology and reduced quality of life in cirrhotic patients with a liver transplant perspective. <i>Metabolic Brain Disease</i> , 2017, 32, 923-933.	1.4	5
112	Skeletal muscle myopenia in mice model of bile duct ligation and carbon tetrachloride-induced liver cirrhosis. <i>Physiological Reports</i> , 2017, 5, e13153.	0.7	27
113	A practical approach to nutritional screening and assessment in cirrhosis. <i>Hepatology</i> , 2017, 65, 1044-1057.	3.6	213
114	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
115	Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 934-936.	2.4	150
116	Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass. <i>Liver International</i> , 2017, 37, 700-706.	1.9	34
117	A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 385-390.	0.7	7
118	Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort. <i>Minerva Gastroenterology</i> , 2017, 64, 1-9.	0.3	3
119	An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. <i>Hepatology</i> , 2016, 63, 1632-1639.	3.6	66
120	Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis. <i>HIV Clinical Trials</i> , 2016, 17, 49-54.	2.0	10
121	Sarcopenia from mechanism to diagnosis and treatment in liver disease. <i>Journal of Hepatology</i> , 2016, 65, 1232-1244.	1.8	436
122	Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors. <i>Digestive and Liver Disease</i> , 2016, 48, 1072-1077.	0.4	20
123	Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. <i>Liver Transplantation</i> , 2016, 22, 1333-1342.	1.3	36
124	HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 739-750.	1.3	13
125	Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 433-441.	1.3	6
126	Primary Prophylaxis of First Variceal Bleeding. , 2016, , 215-224.		2

#	ARTICLE	IF	CITATIONS
127	Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. <i>American Journal of Gastroenterology</i> , 2016, 111, 523-528.	0.2	63
128	What is new about diet in hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2016, 31, 1289-1294.	1.4	30
129	No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. <i>Metabolic Brain Disease</i> , 2016, 31, 1275-1281.	1.4	26
130	Hemostasis in uncontrolled esophageal variceal bleeding by self-expanding metal stents: a systematic review. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2016, 9, 6-11.	0.6	1
131	Corrigendum to "Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?" [Hepatology 63 (2015) 309-311]. <i>Journal of Hepatology</i> , 2015, 63, 1298.	1.8	0
132	Management of hepatic encephalopathy as an inpatient. <i>Clinical Liver Disease</i> , 2015, 5, 79-82.	1.0	6
133	Sarcopenia in liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 328-334.	0.8	152
134	Spontaneous bacterial peritonitis due to methicillin-resistant <i>Staphylococcus aureus</i> in a patient with cirrhosis: the potential role for daptomycin and review of the literature. <i>Gastroenterology Insights</i> , 2015, 7, 6127.	0.7	6
135	Reply to: "The Possible Role of Anti-Methicillin-Resistant <i>Staphylococcus Aureus</i> Antimicrobial Agents in Spontaneous Bacterial Peritonitis". <i>Gastroenterology Insights</i> , 2015, 7, 6356.	0.7	0
136	Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?. <i>Journal of Hepatology</i> , 2015, 63, 309-311.	1.8	37
137	The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey. <i>PLoS ONE</i> , 2015, 10, e0127448.	1.1	78
138	Interaction between infection and hepatic encephalopathy. <i>Journal of Hepatology</i> , 2015, 62, 746-747.	1.8	3
139	A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1346-1352.	2.4	50
140	Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. <i>Hepatology</i> , 2015, 62, 567-574.	3.6	283
141	Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story?. <i>Journal of Hepatology</i> , 2015, 63, 767-768.	1.8	5
142	Beta-blockers in patients with cirrhosis and infections: don't blame too soon!. <i>Liver International</i> , 2015, 35, 1778-1779.	1.9	0
143	The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. <i>Liver International</i> , 2015, 35, 362-369.	1.9	88
144	Changes in nutritional status after liver transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 10682.	1.4	44

#	ARTICLE	IF	CITATIONS
145	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	0.6	27
146	Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome. <i>Liver International</i> , 2014, 34, e290-301.	1.9	4
147	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, 632-638.	0.4	11
148	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.4	3
149	P473 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY. <i>Journal of Hepatology</i> , 2014, 60, S227.	1.8	6
150	The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post-liver transplant (LT) HCV recurrence. <i>Digestive and Liver Disease</i> , 2014, 46, e41.	0.4	0
151	P41 DOES THE GUT MICROBIOTA MODULATE THE INFLAMMATORY STATE IN CIRRHOTIC HOST?. <i>Journal of Hepatology</i> , 2014, 60, S80.	1.8	1
152	Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 83-86.	0.8	20
153	Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 16795.	1.4	187
154	Beta-blockers in liver cirrhosis. <i>Annals of Gastroenterology</i> , 2014, 27, 20-26.	0.4	25
155	Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. <i>Metabolic Brain Disease</i> , 2013, 28, 239-243.	1.4	92
156	Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. <i>Metabolic Brain Disease</i> , 2013, 28, 281-284.	1.4	201
157	Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. <i>Clinical Research in Cardiology</i> , 2013, 102, 859-864.	1.5	16
158	598 IN VITRO EFFECT OF n-6/n-3 POLYUNSATURATED FATTY ACIDS ON PLATELET NOX2-MEDIATED OXIDATIVE STRESS IN LIVER CIRRHOSIS. <i>Journal of Hepatology</i> , 2013, 58, S244-S245.	1.8	0
159	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	0.8	7
160	620 IS THE DIAGNOSIS OF IDIOPATHIC NON-CIRRHOTIC PORTAL HYPERTENSION BE CONSIDERED IN PATIENTS WITH PRIMARY ANTIBODY DEFICIENCIES?. <i>Journal of Hepatology</i> , 2013, 58, S253-S254.	1.8	0
161	157 BONE DISORDERS BEFORE AND AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2013, 58, S70.	1.8	1
162	158 RESPONSE PREDICTION IN CHRONIC HEPATITIS C AFTER LIVER TRANSPLANT BY ASSESSMENT ENT-1-RELATED SINGLE NUCLEOTIDE POLYMORPHISMS. <i>Journal of Hepatology</i> , 2013, 58, S71.	1.8	1

#	ARTICLE	IF	CITATIONS
163	213 BETABLOCKERS AND A PROPER USE OF PROTON PUMP INHIBITORS MAY REDUCE THE RISK OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S92-S93.	1.8	0
164	197 FACTORS RELATED TO HOSPITALIZATION BUT NOT THE SEVERITY OF THE LIVER DISEASE INCREASE THE RISK OF NOSOCOMIAL INFECTION IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S86-S87.	1.8	0
165	Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. <i>European Journal of Internal Medicine</i> , 2013, 24, 172-176.	1.0	67
166	Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. <i>Journal of Hepatology</i> , 2013, 59, 243-250.	1.8	72
167	Mu<scp>RF</scp> and p<scp>GSK</scp> expression in muscle atrophy of cirrhosis. <i>Liver International</i> , 2013, 33, 714-721.	1.9	33
168	Graft macrosteatosis and time of T<tube removal as risk factors for biliary strictures after liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, E332-8.	0.8	13
169	Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2013, 95, 1148-1153.	0.5	35
170	Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up. <i>European Review for Medical and Pharmacological Sciences</i> , 2013, 17, 2718-20.	0.5	8
171	Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence. <i>Journal of Chemotherapy</i> , 2012, 24, 369-372.	0.7	0
172	Recipient Interleukin-28B Rs12979860 C/T Polymorphism and Acute Cellular Rejection After Liver Transplantation. <i>Transplantation</i> , 2012, 93, 1038-1044.	0.5	10
173	Conversion from Twice-Daily to Once-Daily Tacrolimus Administration in Liver Transplant Patient: Results of Long Term Follow-Up. <i>Transplantation</i> , 2012, 94, 749-750.	0.5	5
174	164 POST-TRANSPLANTATION METABOLIC SYNDROME: IS IT ONLY A THERAPEUTIC CONCERN?. <i>Journal of Hepatology</i> , 2012, 56, S72.	1.8	0
175	589 OXIDATIVE STRESS AND INFLAMMATION IN LIVER CIRRHOSIS: ROLE OF N-6/N-3 POLYUNSATURATED FATTY ACIDS BALANCE. <i>Journal of Hepatology</i> , 2012, 56, S234.	1.8	0
176	667 TERLIPRESSIN AND ALBUMIN VS MIDODRINE PLUS OCTREOTIDE AND ALBUMIN IN THE TREATMENT OF HRS IN PATIENTS WITH CIRRHOSIS: RESULTS OF A CONTROLLED CLINICAL TRIAL BY AISF. <i>Journal of Hepatology</i> , 2012, 56, S264.	1.8	1
177	Occurrence of Chronic Renal Failure in Liver Transplantation: Monitoring of Pre- and Posttransplantation Renal Function. <i>Transplantation Proceedings</i> , 2012, 44, 1956-1959.	0.3	11
178	O9 BACTERIAL INFECTIONS INDUCE BOTH OVERT AND MINIMAL HEPATIC ENCEPHALOPATHY: RESULTS OF A PROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2012, 44, S238.	0.4	0
179	Bacterial resistance in cirrhotic patients: An emerging reality. <i>Journal of Hepatology</i> , 2012, 56, 756-757.	1.8	13
180	Metabolic Syndrome and Cardiovascular Risk after Liver Transplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2012, 44, 2005-2006.	0.3	22

#	ARTICLE	IF	CITATIONS
181	Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. <i>Clinics in Liver Disease</i> , 2012, 16, 133-146.	1.0	122
182	Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , 2012, 25, 448-454.	0.8	11
183	Nutrition and Hepatic Encephalopathy. , 2012, , 199-209.		1
184	A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 613-616.e1.	2.4	26
185	Evidence of Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 181-183.	2.4	99
186	T-23 Poor adherence to pegylated interferon and ribavirin is a major concern in the treatment of hepatitis C after liver transplantation: Evidence from the AISF RECOLT-C study group. <i>Digestive and Liver Disease</i> , 2011, 43, S84.	0.4	0
187	P.1.5: POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP. <i>Digestive and Liver Disease</i> , 2011, 43, S149.	0.4	0
188	Transjugular intrahepatic portosystemic shunt with expanded-polytetrafluoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. <i>Digestive and Liver Disease</i> , 2011, 43, 78-84.	0.4	71
189	Vascular disorders of the liver: Recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. <i>Digestive and Liver Disease</i> , 2011, 43, 503-514.	0.4	59
190	Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. <i>European E-journal of Clinical Nutrition and Metabolism</i> , 2011, 6, e142-e147.	0.4	24
191	Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. <i>Journal of Hepatology</i> , 2011, 55, 1241-1248.	1.8	87
192	Nutritional Status and Liver Transplantation. <i>Journal of Clinical and Experimental Hepatology</i> , 2011, 1, 190-198.	0.4	30
193	P.1.276: ALBUMIN ADMINISTRATION SUPPORTS CARDIAC OUTPUT IN CIRRHOTIC PATIENTS AFTER TOTAL PARACENTESIS. <i>Digestive and Liver Disease</i> , 2011, 43, S240.	0.4	0
194	P.1.318: CHANGES IN BODY COMPOSITION IN THE FIRST MONTHS AFTER LIVER TRANSPLANTATION. <i>Digestive and Liver Disease</i> , 2011, 43, S253-S254.	0.4	0
195	172 PROPHYLAXIS WITH BETA-BLOCKERS AND LOWER USE OF PROTON PUMP INHIBITORS MAY REDUCE THE PREVALENCE OF INFECTIONS IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2011, 54, S74.	1.8	0
196	187 SEPSIS REPRESENTS A NEGATIVE PROGNOSTIC FACTOR IN SHORT AND LONG TERM IN HOSPITALIZED CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2011, 54, S80.	1.8	0
197	427 TREATMENT OF HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: GENDER ISSUE ON THERAPY OUTCOME. <i>Journal of Hepatology</i> , 2011, 54, S173.	1.8	0
198	532 POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP. <i>Journal of Hepatology</i> , 2011, 54, S218.	1.8	1

#	ARTICLE	IF	CITATIONS
199	540 VALIDATION OF A PREDICTIVE MODEL FOR CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S221.	1.8	0
200	Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study. <i>Antiviral Therapy</i> , 2011, 16, 879-885.	0.6	8
201	Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. <i>Liver International</i> , 2011, 31, 1505-1510.	1.9	43
202	<sc>NADPH</sc> oxidase-mediated platelet isoprostane overproduction in cirrhotic patients: implication for platelet activation. <i>Liver International</i> , 2011, 31, 1533-1540.	1.9	37
203	Impact of Anti-Hepatitis B Core-Positive Donors in Liver Transplantation: A Survival Analysis. <i>Transplantation Proceedings</i> , 2011, 43, 274-276.	0.3	3
204	Acute Renal Failure in Liver Transplant Recipients: Role of Pretransplantation Renal Function and 1-Year Follow-Up. <i>Transplantation Proceedings</i> , 2011, 43, 1136-1138.	0.3	17
205	Nutritional status: its influence on the outcome of patients undergoing liver transplantation. <i>Liver International</i> , 2010, 30, 208-214.	1.9	233
206	Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1374-1381.	0.2	49
207	Long-term effect of liver transplantation on cirrhotic autonomic cardiac dysfunction. <i>Digestive and Liver Disease</i> , 2010, 42, 131-136.	0.4	15
208	Atorvastatin-Induced Prolonged Cholestasis with Bile Duct Damage. <i>Clinical Drug Investigation</i> , 2010, 30, 205-209.	1.1	10
209	Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial. <i>Journal of Hepatology</i> , 2010, 53, 267-272.	1.8	129
210	Bone Disorders in Patients With Chronic Liver Disease Awaiting Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1191-1193.	0.3	40
211	RIFLE Criteria and Hepatic Function in the Assessment of Acute Renal Failure in Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1233-1236.	0.3	47
212	Conversion From Twice-Daily to Once-Daily Tacrolimus Administration in Liver Transplant Patient. <i>Transplantation Proceedings</i> , 2010, 42, 1322-1324.	0.3	20
213	165 MELD, PROTEIN MALNUTRITION AND PREVIOUS INFECTIONS ARE PREDICTORS OF BACTERIAL INFECTIONS AND SEPSIS IN CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S72.	1.8	0
214	176 BACTERIAL INFECTIONS AND SEPSIS ACUTELY DETERIORATE LIVER FUNCTION IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2010, 52, S76.	1.8	0
215	191 CLINICAL EFFICACY OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATED WITH COVERED STENTS WITH DIFFERENT DIAMETERS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. <i>Journal of Hepatology</i> , 2010, 52, S82-S83.	1.8	2
216	192 INHIBITORY CONTROL TEST DOES NOT IDENTIFY THE PATIENTS AT RISK OF DEVELOPING OVERT HE IN AN ITALIAN POPULATION OF CIRRHOTIC PATIENTS. <i>Journal of Hepatology</i> , 2010, 52, S83.	1.8	0

#	ARTICLE	IF	CITATIONS
217	474 THE PREDICTION OF CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION: A TIME-DEPENDENT ANALYSIS. <i>Journal of Hepatology</i> , 2010, 52, S192.	1.8	0
218	Cirrhotic Patients Are at Risk for Health Care-Associated Bacterial Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 979-985.e1.	2.4	274
219	Dietary and nutritional indications in hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2009, 24, 211-221.	1.4	38
220	Phagocytosis of gadolinium chloride or zymosan induces simultaneous upregulation of hepcidin- and downregulation of hemojuvelin- and Fpn-1-gene expression in murine liver. <i>Laboratory Investigation</i> , 2009, 89, 1252-1260.	1.7	25
221	Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and ß-actin protein. <i>Liver International</i> , 2009, 29, 103-112.	1.9	10
222	Predictive Factors of Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Multivariate Analysis. <i>Transplantation Proceedings</i> , 2009, 41, 1306-1309.	0.3	23
223	Immune-mediated liver dysfunction after antiviral treatment in liver transplanted patients with hepatitis c: Allo or autoimmune de novo hepatitis?. <i>Digestive and Liver Disease</i> , 2009, 41, 345-349.	0.4	31
224	Predictive risk factors of recurrence of hepatocellular carcinoma after liver transplantation. <i>Digestive and Liver Disease</i> , 2009, 41, A16.	0.4	0
225	Do We Really Need Alternatives to Polymorphonuclear Cells Counting in Ascitic Fluid?. <i>Gastroenterology</i> , 2009, 136, 728-729.	0.6	2
226	160 ONE MONTH POST-OPERATIVE SERUM INSULIN PREDICTS SERUM AMINOTRANSFERASE ELEVATION AND FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S68.	1.8	0
227	165 DONOR/RECIPIENT BODY SURFACE AREA RATIO AS A NOVEL PREDICTOR OF GRAFT SURVIVAL AFTER DECEASED DONOR LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2009, 50, S70.	1.8	0
228	464 CHRONIC RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION: RISK FACTORS AND A NEW PREDICTIVE SCORE. <i>Journal of Hepatology</i> , 2009, 50, S175.	1.8	1
229	Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. <i>Liver Transplantation</i> , 2008, 14, 806-814.	1.3	80
230	Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts. <i>American Journal of Gastroenterology</i> , 2008, 103, 2738-2746.	0.2	239
231	Transjugular intrahepatic portosystemic shunt (TIPS) is feasible in non-cirrhotic patients with cavernomatous transformation of the portal vein. <i>Digestive and Liver Disease</i> , 2008, 40, A9-A10.	0.4	0
232	Combined Liver-Kidney Transplantation in Polycystic Disease: Case Reports. <i>Transplantation Proceedings</i> , 2008, 40, 2075-2076.	0.3	13
233	201 COMBINED THERAPY WITH LOW DOSE HEPATITIS B IMMUNOGLOBULIN (HBIG) AND LAMIVUDINE (LAM) IN PATIENTS TRANSPLANTED FOR HBV CHRONIC LIVER DISEASE: LONG TERM EFFICACY AND COSTS. <i>Journal of Hepatology</i> , 2008, 48, S84.	1.8	5
234	296 EFFICACY OF ASCITES CLUB GUIDELINES FOR THE TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS IN THE CLINICAL PRACTICE. <i>Journal of Hepatology</i> , 2008, 48, S118.	1.8	1

#	ARTICLE	IF	CITATIONS
235	Cholestasis Induced by Total Parenteral Nutrition. <i>Clinics in Liver Disease</i> , 2008, 12, 97-110.	1.0	75
236	Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. <i>World Journal of Gastroenterology</i> , 2008, 14, 2757.	1.4	82
237	Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 5689.	1.4	19
238	Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2007, 39, 1895-1897.	0.3	9
239	Does nutritional status influence the outcome in patients undergoing liver transplantation in the "MELD" era?. <i>Digestive and Liver Disease</i> , 2007, 39, A41.	0.4	0
240	Short-term changes in nutritional status, energy expenditure, dietary intake in patients undergoing liver transplantation. <i>Digestive and Liver Disease</i> , 2007, 39, A41.	0.4	0
241	Chronic renal dysfunction after liver transplantation: Incidence and risk factors. <i>Digestive and Liver Disease</i> , 2007, 39, A42.	0.4	0
242	A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 1009-1017.	1.8	96
243	204 Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (tips): PTFE-covered stent grafts versus bare stents. <i>Journal of Hepatology</i> , 2006, 44, S84.	1.8	0
244	Total parenteral nutrition-related gastroenterological complications. <i>Digestive and Liver Disease</i> , 2006, 38, 623-642.	0.4	87
245	High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: A case-control study. <i>Hepatology</i> , 2005, 42, 1158-1165.	3.6	164
246	Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 140-151.	1.3	24
247	Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. <i>Digestive and Liver Disease</i> , 2005, 37, 349-356.	0.4	245
248	Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. <i>Journal of Hepatology</i> , 2005, 42, 674-679.	1.8	202
249	Failure of hepatitis B vaccination to induce either humoral or cellular immune response after liver transplantation for hepatitis B related cirrhosis. <i>Journal of Hepatology</i> , 2005, 43, 1089-1090.	1.8	11
250	Predictive Factors of Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2005, 37, 2535-2540.	0.3	31
251	Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism†Multicentre prospective study by the "Nutritional Problems in Gastroenterology" Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2005, 37, 681-688.	0.4	76
252	The Natural History of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis and Mild Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2004, 99, 1959-1965.	0.2	98

#	ARTICLE	IF	CITATIONS
253	Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. <i>Hepatology</i> , 2004, 40, 629-635.	3.6	327
254	Polytetrafluoroethylene-Covered Stent Grafts for TIPS Procedure: 1-Year Patency and Clinical Results. <i>American Journal of Gastroenterology</i> , 2004, 99, 280-285.	0.2	73
255	Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 535-538.	0.3	52
256	100 Peginterferon alfa-2A (40KD) with or without ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Preliminary report of a randomized study. <i>Journal of Hepatology</i> , 2004, 40, 38.	1.8	4
257	155 Predictors of outcome of liver transplantation in patients with liver cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2004, 40, 52.	1.8	0
258	220 Randomised controlled trial for the prevention of hepatic encephalopathy after transjugular intrahepatic porto-systemic shunt (TIPS): Comparison between lactitol, rifaximin and no treatment. <i>Journal of Hepatology</i> , 2004, 40, 70-71.	1.8	1
259	Is hyperammonemia really the true cause of altered neuropsychology, brain MR spectroscopy and magnetization transfer after an oral amino acid load in cirrhosis?. <i>Hepatology</i> , 2003, 38, 777-777.	3.6	5
260	Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients. <i>Metabolic Brain Disease</i> , 2003, 18, 27-35.	1.4	18
261	Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. <i>Clinical Nutrition</i> , 2003, 22, 553-559.	2.3	57
262	TIPS for patients awaiting orthotopic liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 999-1000.	1.3	2
263	Donor arterial oxygen pressure is a major determinant of early post-operative adverse events in adult liver transplant recipients. <i>Gastroenterology</i> , 2003, 124, A738.	0.6	0
264	First post-transplant day ALT serum concentration predicts early hepatitis C recurrence after liver transplantation (LT). <i>Gastroenterology</i> , 2003, 124, A732.	0.6	0
265	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. <i>Gastroenterology</i> , 2003, 124, 1792-1801.	0.6	554
266	Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. <i>American Journal of Gastroenterology</i> , 2003, 98, 1844-1848.	0.2	67
267	Incidence and natural history of small esophageal varices in cirrhotic patients. <i>Journal of Hepatology</i> , 2003, 38, 266-272.	1.8	466
268	Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. <i>Journal of Hepatology</i> , 2003, 38, 441-446.	1.8	119
269	QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. <i>Journal of Hepatology</i> , 2003, 38, 461-467.	1.8	88
270	PTFE-covered stent-grafts for tips procedure: One-year patency and clinical results. <i>Journal of Hepatology</i> , 2003, 38, 66.	1.8	1

#	ARTICLE	IF	CITATIONS
271	Prevalence and clinical relevance of spontaneous porto-systemic shunts in cirrhotic patients with recurrent hepatic encephalopathy: A case control study. <i>Journal of Hepatology</i> , 2003, 38, 58.	1.8	0
272	Intractable Hepatic Encephalopathy After Tips with Polytetrafluoroethylene-covered Stent-Graft. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 570-572.	0.6	9
273	Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). <i>American Journal of Gastroenterology</i> , 2002, 97, 142-148.	0.2	98
274	MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. <i>Journal of Hepatology</i> , 2002, 36, 494-500.	1.8	248
275	Hyperdynamic circulation after tips implantation: its effects on neurohumoral system. <i>Journal of Hepatology</i> , 2002, 36, 201-202.	1.8	0
276	Preliminary results of a randomised controlled trials in the prevention of early post-tips hepatic encephalopathy: a comparison between rifaximin and lactitol. <i>Journal of Hepatology</i> , 2002, 36, 205.	1.8	1
277	Role of the determination of partial pressure of ammonia in cirrhotic patients with hepatic encephalopathy. <i>Journal of Hepatology</i> , 2002, 36, 207.	1.8	0
278	Malnutrition is a risk factor in cirrhotic patients undergoing surgery. <i>Nutrition</i> , 2002, 18, 978-986.	1.1	127
279	Endoscopic screening for esophageal varices in cirrhotic patients. <i>Hepatology</i> , 2002, 35, 501-502.	3.6	38
280	Factors associated with poor health-related quality of life of patients with cirrhosis. <i>Gastroenterology</i> , 2001, 120, 170-178.	0.6	431
281	Accuracy of the mayo clinic model to predict survival in patients with elective tips. <i>Journal of Hepatology</i> , 2001, 34, 31.	1.8	0
282	Validation of a model predicting survival in patients with tips. <i>Journal of Hepatology</i> , 2001, 34, 52.	1.8	0
283	Bone density and nutritional assessment in cirrhotic patients. <i>Journal of Hepatology</i> , 2001, 34, 76.	1.8	0
284	Response to Drs. Piscaglia et al.. <i>American Journal of Gastroenterology</i> , 2001, 96, 2504-2505.	0.2	0
285	Effect of Sodium Benzoate on Blood Ammonia Response To Oral Glutamine Challenge in Cirrhotic Patients: A Note of Caution. <i>American Journal of Gastroenterology</i> , 2000, 95, 3574-3578.	0.2	35
286	Energy expenditure and caloric intake in patients with stable cirrhosis with or without malnutrition. <i>Gastroenterology</i> , 2000, 118, A1482.	0.6	0
287	Modification of cardiac function in cirrhotic patients with and without ascites. <i>American Journal of Gastroenterology</i> , 2000, 95, 3200-3205.	0.2	133
288	Transjugular intrahepatic porta-systemic shunt (TIPS) VS.endoscopic sclerotherapy (ES) for the prevention of variceal rebleeding in cirrhosis: A meta-analysis using individual data of 432 patients from 5 randomized controlled trials. <i>Gastroenterology</i> , 2000, 118, A1434.	0.6	0

#	ARTICLE	IF	CITATIONS
289	TIPS versus paracentesis in the treatment of refractory ascites: Preliminary results of a randomized controlled trial. <i>Gastroenterology</i> , 2000, 118, A980.	0.6	4
290	Sodium benzoate increases blood ammonia levels in cirrhotic patients. <i>Gastroenterology</i> , 2000, 118, A981.	0.6	0
291	Serum leptin levels in cirrhosis. <i>Gastroenterology</i> , 2000, 118, A1469.	0.6	0
292	Clinical nutrition practice in Italian Gastroenterology Units. <i>Digestive and Liver Disease</i> , 2000, 32, 473-479.	0.4	7
293	Leptin in cirrhotic patients. <i>Journal of Hepatology</i> , 2000, 32, 213.	1.8	0
294	TIPS: Refractory Ascites and Encephalopathy. <i>Medical Radiology</i> , 2000, , 297-303.	0.0	1
295	Effect of Lactitol on Blood Ammonia Response to Oral Glutamine Challenge in Cirrhotic Patients: Evidence for An Effect of Nonabsorbable Disaccharides on Small Intestine Ammonia Generation. <i>American Journal of Gastroenterology</i> , 1999, 94, 3323-3327.	0.2	23
296	Cost analysis for the prevention of variceal rebleeding: A comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of italian cirrhotic patients. <i>Hepatology</i> , 1999, 29, 1074-1077.	3.6	60
297	Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. <i>Hepatology</i> , 1999, 30, 649-654.	3.6	84
298	A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients. <i>Clinical Nutrition</i> , 1999, 18, 349-351.	2.3	39
299	Recent Developments in Trace Element Analysis in the Prevention, Diagnosis, and Treatment of Diseases. <i>Microchemical Journal</i> , 1998, 59, 194-202.	2.3	32
300	Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial. <i>Hepatology</i> , 1998, 27, 48-53.	3.6	172
301	Use of the stable isotope ⁶⁵ Cu test for the screening of Wilson's disease in a family with two affected members. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30, 270-5.	0.5	8
302	Management of Hepatic Encephalopathy. <i>New England Journal of Medicine</i> , 1997, 337, 1921-1922.	13.9	22
303	Impaired nonoxidative glucose metabolism in patients with liver cirrhosis: Effects of two insulin doses. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 840-843.	1.5	14
304	ESPEN guidelines for nutrition in liver disease and transplantation. <i>Clinical Nutrition</i> , 1997, 16, 43-55.	2.3	345
305	Whole body and regional body composition analysis by dual-energy X-ray absorptiometry in cirrhotic patients. <i>European Journal of Clinical Nutrition</i> , 1997, 51, 810-814.	1.3	45
306	Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 1997, 77, 044-047.	1.8	77

#	ARTICLE	IF	CITATIONS
307	Increased nonoxidative glucose metabolism in idiopathic reactive hypoglycemia. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 606-610.	1.5	16
308	Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. <i>Digestive Diseases and Sciences</i> , 1996, 41, 578-584.	1.1	127
309	Does malnutrition affect survival in cirrhosis?. <i>Hepatology</i> , 1996, 23, 1041-1046.	3.6	315
310	Does malnutrition affect survival in cirrhosis?. <i>Hepatology</i> , 1996, 23, 1041-1046.	3.6	47
311	Intravascular hemolysis and transjugular intrahepatic portosystemic stent shunt. <i>Journal of Hepatology</i> , 1994, 20, 152-153.	1.8	6
312	Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic Fibrosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1994, 19, 198-203.	0.9	39
313	Nutritional status in liver cirrhosis. <i>The Italian Journal of Gastroenterology</i> , 1993, 25, 400-1.	0.1	10
314	Early Postprandial Energy Expenditure and Macronutrient Use After a Mixed Meal in Cirrhotic Patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 1992, 16, 445-450.	1.3	22
315	The Effect of Lactulose and Lactitol Administration on Fecal Fat Excretion in Patients with Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 1992, 15, 125-127.	1.1	20
316	Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. <i>Hepatology</i> , 1992, 16, 785-789.	3.6	92
317	Increased energy expenditure in cirrhotic patients with hepatocellular carcinoma. <i>Nutrition</i> , 1992, 8, 321-5.	1.1	8
318	Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1204-1208.	1.1	121
319	Measurement of Resting Energy Expenditure in Patients with Liver Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 1991, 15, 694-694.	1.3	1
320	Effect of Lactitol and Lactulose Administration on the Fecal Flora in Cirrhotic Patients. <i>Journal of Clinical Gastroenterology</i> , 1990, 12, 433-436.	1.1	96
321	Basal energy production rate and substrate use in stable cirrhotic patients. <i>Hepatology</i> , 1990, 12, 106-112.	3.6	147
322	Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 787-795.	1.8	10
323	Influence of leucine infusion on intracellular amino acids in humans. <i>European Journal of Clinical Investigation</i> , 1990, 20, 293-298.	1.7	41
324	Malabsorption and nutritional abnormalities in patients with liver cirrhosis. <i>The Italian Journal of Gastroenterology</i> , 1990, 22, 118-23.	0.1	45

#	ARTICLE	IF	CITATIONS
325	Lactitol in the treatment of chronic hepatic encephalopathy—a randomized cross-over comparison with lactulose. <i>Hepato-Gastroenterology</i> , 1990, 37, 524-7.	0.5	10
326	Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. <i>Digestive Diseases and Sciences</i> , 1989, 34, 823-829.	1.1	39
327	Carbon Tetrachloride-Induced Experimental Cirrhosis in the Rat: A Reappraisal of the Model. <i>European Surgical Research</i> , 1989, 21, 280-286.	0.6	42
328	From meetings. <i>Research in Clinic and Laboratory</i> , 1988, 18, 330-373.	0.3	0
329	Optimal Nutritional Indexes in Chronic Liver Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 1987, 11, 130S-134S.	1.3	91
330	Composition of Free Fatty Acids and Adipose Tissue Triglycerides in Portacaval Shunted Rats. <i>European Surgical Research</i> , 1987, 19, 151-158.	0.6	1
331	Hepatic encephalopathy: Lack of changes of \hat{I}^3 -aminobutyric acid content in plasma and cerebrospinal fluid. <i>Hepatology</i> , 1987, 7, 816-820.	3.6	34
332	Splanchnic and leg exchange of free fatty acids in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 1986, 3, 348-355.	1.8	57
333	Fatty acid composition of adipose tissue in patients with chronic liver disease. <i>Journal of Hepatology</i> , 1986, 3, 104-110.	1.8	12
334	Malnutrition in Chronic Liver Disease. , 1985, , 195-203.		1
335	Aminoacid imbalance and malnutrition in liver cirrhosis. <i>Clinical Nutrition</i> , 1985, 4, 249-253.	2.3	17
336	Total and individual free fatty acid concentrations in liver cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1984, 33, 646-651.	1.5	54
337	The Pros and the Cons of the Amino Acid Neurotransmitter Hypothesis. , 1984, , 460-471.		0
338	Branched-Chain Amino Acids in the Treatment of Severe Hepatic Encephalopathy. , 1984, , 335-344.		8
339	Glucose intolerance in liver cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1982, 31, 627-634.	1.5	70
340	Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 1982, 27, 828-832.	1.1	80
341	Branched-chain amino acids vs lactulose in the treatment of hepatic coma. <i>Digestive Diseases and Sciences</i> , 1982, 27, 929-935.	1.1	157